What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis

What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis

Carmen Fucile,1 Francesca Mattioli,1 Valeria Marini,1 Massimo Gregori,2 Aurelio Sonzogni,3 Antonietta Martelli,1 Natalia Maximova4 1Pharmacology and Toxicology Unit, University of Genoa, Genoa, Italy; 2Department of Pediatric Radiology, Institute for Maternal and Child Health – IRCCS Burl...

Full description

Bibliographic Details
Main Authors: Fucile C, Mattioli F, Marini V, Gregori M, Sonzogni A, Martelli A, Maximova N
Format: Article
Language:English
Published: Dove Medical Press 2018-09-01
Series:Therapeutics and Clinical Risk Management
Subjects:
deferasirox
allogeneic hematopoietic stem cell transplantation (allo-HSCT)
pediatric
ductopenia
therapeutic drug monitoring
adverse events
Online Access:https://www.dovepress.com/what-is-known-about-deferasirox-chelation-therapy-in-pediatric-hsct-re-peer-reviewed-article-TCRM

Internet

https://www.dovepress.com/what-is-known-about-deferasirox-chelation-therapy-in-pediatric-hsct-re-peer-reviewed-article-TCRM

Similar Items